1. Advances in Managing Inhibitors in Patients With Hemophilia A

2. Caregiver Interview Marquita Reinhardt

3. Patient History  

4. Treatment Approach

5. Challenges

6. Effect on Patient

7. Advances in Managing Inhibitors in Patients With Hemophilia A

9. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

10. Inhibitors

11. Risk Factors

12. Management of Acute Bleeds

13. ITI

14. Predictors of ITI Success

15. Further Considerations for ITI

16. EHL Factor Products for ITI

17. Challenges of Managing Inhibitors

18. Burden of Care

19. Emicizumab

20. HAVEN 1 Results

21. Adverse Events

22. Updated Results

23. Clinician Experience

24. Changes to Practice

25. Novel Approaches Overcoming Inhibitors

26. Fitusiran

27. Further "Off-Switch" Approaches

28. ITI in the Context of Emicizumab and Novel Therapies

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)